Apogee Therapeutics, Inc. ( (APGE)) has released its Q3 earnings. Here is a breakdown of the information Apogee Therapeutics, Inc. presented to its investors. Apogee Therapeutics, Inc. is a ...

Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Allspring Global Investments Holdings LLC lessened its holdings in Apogee Therapeutics, Inc. (NASDAQ:APGE – Free Report) by 6 ...

Pharmacokinetic data up to 9 months continue to support potential best-in-class profile, including a half-life of approximately 75 days, approximately three to five times that of currently ...

SAN FRANCISCO and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for ...

Apogee Therapeutics (APGE) announced updated positive results from its ongoing Phase 1 clinical trial of APG777, a novel half-life extended anti-IL-13 antibody for the treatment for atopic ...

SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for ...

Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and ...

A live and archived webcast of the fireside chats and presentations will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. Apogee Therapeutics is ...